Comparative Pharmacology
Head-to-head clinical analysis: NICODERM CQ versus NICOTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICODERM CQ versus NICOTINE.
NICODERM CQ vs NICOTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine is a nicotinic cholinergic receptor agonist that stimulates ganglia and the CNS, leading to release of catecholamines and other neurotransmitters. In smoking cessation, it acts as a replacement therapy to reduce withdrawal symptoms and cravings by binding to nicotinic acetylcholine receptors in the brain.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
Apply one 7 mg/24 hour, 14 mg/24 hour, or 21 mg/24 hour transdermal patch to non-hairy, clean, dry skin on the upper body or upper outer arm once daily. Initial dose based on smoking status: patients smoking >10 cigarettes/day: 21 mg/24 hours; patients smoking ≤10 cigarettes/day: 14 mg/24 hours. Titrate based on withdrawal symptoms.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
Clinical Note
moderateNicotine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Nicotine."
Clinical Note
moderateNicotine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nicotine resulting in a loss in efficacy."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life ~2 hours (range 1-4 h) after transdermal patch removal; clinically, levels decline rapidly, requiring scheduled reapplication.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
Primarily renal; about 10-20% excreted unchanged, remainder as metabolites (cotinine and nicotine-N'-oxide). Total clearance ~1.2 L/min. Biliary/fecal excretion negligible (<5%).
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Category C
Category C
Smoking cessation aid
Smoking cessation aid
Nicotine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Nicotine."